Please login to the form below

Not currently logged in
Email:
Password:

GSK immunotherapy

This page shows the latest GSK immunotherapy news and features for those working in and with pharma, biotech and healthcare.

GSK pays $50m upfront to tap Immatics’ cell therapy platform

GSK pays $50m upfront to tap Immatics’ cell therapy platform

GSK is just the latest in a series of drugmakers to cut deals with Immatics for access to its cell therapy expertise, and it has previously partnered withRoche and Genmab. ... GSK took full ownership of the therapy in 2018. GSK’s push into cancer has

Latest news

  • GSK divests travel vaccines to Bavarian Nordic as part of strategic refocus GSK divests travel vaccines to Bavarian Nordic as part of strategic refocus

    The revamp at GSK was needed in large part due to generic competition to its blockbuster respiratory treatment Advair. ... GSK can't catch up with immunotherapy leaders, such as Merck &Co’s Keytruda and Bristol-Myers Squibb’s Opdivo, but its R&D

  • GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn

    It also adds to its existing IO alliance with UK biotech Immunocore in novel T-cell immunotherapy. ... For GSK, the Merck deal signals its willingness to take a lead in cutting edge immune-oncology.

  • GSK upbeat on its return to oncology market GSK upbeat on its return to oncology market

    Barron says this didn’t drive the acquisition, but said it would help GSK develop its own in-house immunotherapy combinations, as well as being in development for endometrial cancer. ... GSK’s other big hope in oncology is its BCMA antibody-drug

  • GSK terminates lung cancer vaccine trial GSK terminates lung cancer vaccine trial

    Unable to identify patients who may benefit from MAGE-A3 immunotherapy. GlaxoSmithKline's (GSK) woes for its investigational cancer vaccine MAGE-A3 continue after the company chose to terminate a ... It is not just lung cancer where GSK has reported

  • Bayer to research cancer immunotherapies with Compugen Bayer to research cancer immunotherapies with Compugen

    Yervoy's success seems to have inspired other companies to invest more in their own cancer immunotherapy efforts, with GlaxoSmithKline (GSK), Roche, AstraZeneca (AZ), Novartis and Merck Serono all initiating major ... Both GSK and Roche are working with

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    GSK's current and future oncology R&D pipeline becoming its preferred commercialisation partner. ... Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...